The association of serum nesfatin-1 and ghrelin levels with metabolic syndrome in patients with schizophrenia

Ünal, Kübranur; Yüksel, Rabia Nazik; Turhan, Turan; Sezer, Sevilay; Yaylacı, Elif Tatlıdil

doi:10.1016/j.psychres.2017.12.041

Cited by 12 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human serum and saliva nesfatin-1 levels (25.8±5.84 ng/mL, 33.5±8.79 ng/ mL, respectively) in untreated epileptic patients were 160 times greater than those of control subjects (0.16±0.002 ng/ mL, 0.21±0.003 ng/mL, respectively). Interestingly, another study determined that the level of nesfatin-1 was higher in patients with schizophrenia compared with a control group (10.51-350.8 pg/mL, 4.86-68.91 pg/mL, respectively) [37]. In our study, a slight increase in the serum level of nesfatin-1 was observed in patients with migraine without aura compared with the healthy group; however, the difference was not statistically significant (p=0.19) ( Table 1).…”

Section: Discussionmentioning

confidence: 98%

Evaluation of Serum Levels of Irisin and Nesfatin-1 in Patients with Migraine without Aura

Akdağ¹

2020

Int J Med Biochem

View full text Add to dashboard Cite

Evaluation of serum levels of irisin and nesfatin-1 in patients with migraine without aura M igraine is defined as a neurovascular disorder with neurogenic inflammation and contractile dysfunction of the cranial blood vessels [1]. It is a headache disorder that is accompanied by different combinations of neurological and autonomic disorders [2]. Clinically, there are 2 classic types of migraine: with and without aura. Migraine without aura is the most frequent form of primary headaches (60-80% of all migraines). The clinical symptoms of migraine without aura include pulsating pain, pain on at least one side of the head, sensitivity to sound and light, and vomiting and/or nausea [3]. Migraine attacks decrease quality of life (QoL), and may also cause a fiscal burden for individuals and organizations due to medical expenses. Inadequate treatment can lead to more frequent migraine attacks and more disruption for the sufferers. According to the World Health Organization (WHO), migraine is a cause of labor loss as a result of the headache pain and distress (ranking 19 th for men and 12 th for women) [4]. Many theories for the pathophysiology of migraine have been proposed. According to a neurovascular theory, migraine headaches demonstrate vascular changes in secondary neuronal activation. As a result of neuronal events, blood vessels in pain-sensitive structures expand and lead to more trigeminal nerve activation and pain [2]. The exact pathology of migraine has yet to be fully understood. In 1 novel study, it was proposed that cytokines and some neuropeptides may have an important role in the pathogenesis of migraine [5]. Recent research has focused on the association between mi-Objectives: Migraine is a chronic neurological disorder. A number of cytokines have been linked to the pathogenesis of migraine. This is a preliminary assessment to determine and analyze the serum levels of irisin and nesfatin-1 in patients with migraine without aura. Methods: A total of 80 participants, 40 patients who had been diagnosed with migraine without aura (10 men, 30 women) and 40 healthy controls (10 men, 30 women), were included in the study. The serum irisin and nesfatin-1 parameters were investigated using blood samples drawn from the patient and control groups. Results: The mean serum irisin level was 16.87±14.66 ng/mL in the migraine group and 17.33±17.18 ng/mL in the healthy controls. No significant p value was determined (p=0.470), but the level was slightly lower in the migraine group. The mean nesfatin-1 level was 4.71±5.96 mmol/L in the migraine group and 4.13±5.41 mmol/L in the healthy controls (p=0.19), again revealing a small but statistically insignificant difference. In addition, there was no statistically significant difference according to age group, visual analog scale score for pain, body mass index, or length of disease duration. Conclusion: Although no statistically significant differences were observed, the present study is believed to be the first to provide insight on the serum levels of irisin and nesfatin...

show abstract

Section: Discussionmentioning

confidence: 98%

Evaluation of Serum Levels of Irisin and Nesfatin-1 in Patients with Migraine without Aura

Akdağ¹

2020

Int J Med Biochem

View full text Add to dashboard Cite

show abstract

“…Renal SOFA score of each patient was calculated and patients were divided into 5 groups according to their creatinine values and urine outputs: creatinine: <1.2 mg/dL (0 point), creatinine: 1.2-1.9 mg/dL (1 points), creatinine: 2-3.4 mg/dL (2 points), creatinine: 3.5-4.9 mg/dLorurine output 200-500 ml/day (3 points), creatinine: > 5 mg/dLorurine output <200 mL/day (4 points) (6)(7)(8). The outcomes of the patients hospitalized in the internal medicine service were evaluated (discharge, referral to the intensive care unit, death).…”

Section: Discussionmentioning

confidence: 99%

“…Administration of Nesfatin-1 in renal ischemic mice has been found to cause a significant decrease in creatinine levels, indicating the future therapeutic effect of Nesfatin-1 (6). It has been shown to cross the bloodbrain barrier and it has an opposite effect on food intake with Ghrelin (7). Recently, a large number of studies were published investigating the effects of Nesfatin-1.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock

TOPRAK¹,

Eruzun²,

KUTLU³

et al. 2022

JECM

View full text Add to dashboard Cite

Nesfatin-1 is an anorectic protein, and we expect it to decrease during sepsis and septic shock. We aimed to analyze it and determine the relationship between Nesfatin-1 levels and quick Sequential Organ Failure Assessment(qSOFA) score, renal Sequential Organ Failure Assessment (SOFA) score, and mortality in patients with sepsis and septic shock. Sixty-nine hospitalized adult patients diagnosed with sepsis and septic shock in the internal medicine department, were included in the study after approval of the Clinical Research Ethics Committee. Sepsis diagnosis was based on the detected focus of infection, positive blood cultures, and response to antibiotics. Twenty-one healthy controls matched for age and sex with these patients were also included in the study. Sixty-nine septic patients and twenty-one healthy volunteers were included in the study. Nesfatin-1 levels were compared with covariates. Nesfatin-1 levels in septic patients were lower than that of healthy controls. There was no significant difference in Nesfatin-1 between diabetic and non-diabetic subgroups. Patients with quick Sequential Organ Failure Assessment (qSOFA) score of three had a statistically significantly lower Nesfatin-1 level than those of patients with the score of zero, one, and two. Nesfatin-1 was correlated negatively with C reactive protein. We found a statistically significant difference in 1-month mortality between Nesfatin-1 levels below and over 80pg/mL. In order to use Nesfatin-1 as a biomarker in differentiating sepsis from healthy population, more comprehensive and more studies are needed. If supported by new studies, Nesfatin-1 levels below 80 pg / mL at first admission in septic patients may direct the clinician to broad-spectrum antibiotic therapy and earlier intensive care follow-up.

show abstract

“…In patients with major depressive disorder 23 or epilepsy 24 elevated nesfatin-1 levels and in patients with generalized anxiety disorder 25 depleted nesfatin-1 levels were determined. Interestingly, another study reported elevated nesfatin-1 levels in schizophrenia patients 26 . Current studies revealed that in traumatic rat brains nesfatin-1 has anti-inflammatory and antiapoptotic effects 27 .…”

Section: Introductionmentioning

confidence: 99%

Serum levels of irisin and nesfatin-1 in multiple sclerosis

Altaş

Uca

Akdağ

et al. 2022

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) is an inflammatory and neurodegenerative autoimmune chronic neurological disease. Currently, there are no effective serum biomarkers to verify MS diagnosis, to assess disease prognosis, and evaluate response to MS treatment. Objective: The present study is a preliminary assessment of irisin and nesfatin-1 serum levels in patients with relapsing- remitting MS (RRMS). Methods: A total of 86 participants, 42 patients with RRMS diagnosis and 44 healthy controls were included in the study. The serum irisin and nesfatin-1 parameters of the patients and control group members were analyzed. Results: Irisin and nesfatin-1 levels of the RRMS patients were significantly lower than the controls (z: -3.82, p<0.001; z: -4.79, p<0.001, respectively) The cut-off level of irisin is 10.390 (ng/mL) (sensitivity: 84.1%, specificity: 71.4%, AUC: 0.800), and the cut-off level of nestatin-1 is 7.155 (ng/mL) (sensitivity: 68.2%, specificity: 64.3%, AUC: 0.739) in the ROC analysis. For these cut-off levels in the case-control groups, the lower irisin and nesfatin-1 levels are the independent variables for MS patients (OR 9.723, 95%CI 2.884-32.785, p<0.001; OR 3.992, 95%CI 1.336-11.928, p<0.001) respectively. Conclusion: The present study revealed lower irisin and nesfatin-1 levels in patients with RRMS. These findings suggest that the decreased levels of irisin and nesfatin-1 peptides may contribute to MS pathogenesis such as inflammation, oxidative stress, and apoptosis in MS, leading to demyelination, axonal damage with neuronal loss, and gliosis.

show abstract

The association of serum nesfatin-1 and ghrelin levels with metabolic syndrome in patients with schizophrenia

Cited by 12 publications

References 38 publications

Evaluation of Serum Levels of Irisin and Nesfatin-1 in Patients with Migraine without Aura

Evaluation of Serum Levels of Irisin and Nesfatin-1 in Patients with Migraine without Aura

Diagnostic and prognostic value of Nesfatin-1 in sepsis and septic shock

Serum levels of irisin and nesfatin-1 in multiple sclerosis

Contact Info

Product

Resources

About